干燥综合征并发间质性肺疾病患者临床特征及其危险因素分析

doi:10.13481/j.1671-587X.20230614

Abstract

Abstract:

Objective To analyze the clinical characteristics and risk factors of the patients with primary Sjogren’s syndrome （pSS） complicated with interstitial lung disease （ILD）， and to improve the clinicians’understandings of the disease， and to provide the evidence for the early detection of extradular organ involvement by the clinicians. Methods The clinical characteristics of 176 patients with pSS were collected and were divided into pSS complicated with ILD group （n=21） and pSS complicated without ILD group （n=155） according to whether the patients were complicated with ILD.The levels of hemoglobin （Hb）， white blood cells （WBC）， platelets （PLT）， C-reactive protein （CRP）， erythrocyte sedimentation rate （ESR），rheumatoid factor （RF），immunoglobulin G （IgG），immunoglobulin M （IgM），immunoglobulin A （IgA）， complement 3 （C3）， complement 4 （C4）， and the positive rates of granular type antinuclear antibodies， cytoplasmic granular type antinuclear antibodies， homogeneous type antinuclear antibodies， anti-SSA， anti-SSB， and anti-Ro-52 antibodies of the patients in two groups were compared.Univariate and multivariate Logistic regression analysis were used to analyze the clinical characteristics and laboratory indexes of the pSS patients complicated with ILD. Results Among the 176 pSS patients， the ratio of male to female was 1∶28， with the median age of 49 （39－58） years and the median course of 24 （24－48） months. Compared with pSS complicated without ILD group，the age of the patients in ILD group was older （P<0.01）， and the level of ESR was increased（P<0.01），the positive rates of cytoplasmic granular type antinuclear antibody and anti-Ro-52 antibody were increased （P<0.01）. The multivariate Logistic regression analysis results showed that the increasing of ESR level （OR=1.046，95% CI： 1.026－1.066， P=0.001） and positive granulosa type （OR=4.676，95% CI： 1.156－18.916， P=0.031） were the risk factors for ILD complicated with pSS. Conclusion The patients with pSS complicated by ILD have an older onset age and higher ESR levels； ILD is more likely to occur when the cytoplasmic granular type antinuclear antibody and anti-Ro-52 antibody of the patients are positive； the increasing of the ESR level and positive coated granular type antinuclear antibody are the risk factors for the pSS complicated with ILD.

Key words: Sjogren’s syndrome, Interstitial lung disease, Anti-Ro52 antibody, Risk factor, Erythrocyte sedimentation rate

CLC Number:

R593.2

Xiunan FENG,Lu CHEN,Yu LONG,Zhenyu JIANG,Ling ZHAO. Analysis on clinical characteristics and risk factors of patients with Sjogren’s syndrome complicated with interstitial lung disease[J].Journal of Jilin University(Medicine Edition), 2023, 49(6): 1513-1518.

Figures/Tables 4

Tab.1

Tab.2

Tab.3

Tab.4

References 27

1	DONG X， ZHOU J F， GUO X J， et al. A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren’s syndrome-related interstitial lung disease in a Chinese population［J］. Clin Rheumatol， 2018， 37（11）：2981-2988.
2	WENG L， CHEN Y， LIANG T， et al. Biomarkers of interstitial lung disease associated with primary Sjögren’s syndrome［J］. Eur J Med Res， 2022， 27（1）： 199.
3	BUVRY C， CASSAGNES L， TEKATH M， et al. Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sjögren syndrome［J］. Respir Med， 2020，63：105895.
4	SHIBOSKI C H， SHIBOSKI S C， SEROR R， et al. 2016 American college of rheumatology/European league against rheumatism classification criteria for primary sjögren’s syndrome： a consensus and data-driven methodology involving three international patient cohorts［J］. Arthritis Rheumatol， 2017， 69（1）： 35-45.
5	SOCIETY A T， SOCIETY E R. American thoracic society/european respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias［J］. Am J Respir Crit Care Med， 2002， 165（2）： 277-304.
6	REINA D， ROIG VILASECA D， TORRENTE-SEGARRA V， et al. Sjögren’s syndrome-associated interstitial lung disease： a multicenter study［J］. Reumatol Clin， 2016， 12（4）： 201-205.
7	PALM O， GAREN T， BERGE ENGER T， et al. Clinical pulmonary involvement in primary Sjogren’s syndrome： prevalence， quality of life and mortality： a retrospective study based on registry data［J］. Rheumatology （Oxford）， 2013， 52（1）： 173-179.
8	KREIDER M， HIGHLAND K. Pulmonary involvement in Sjögren syndrome［J］. Semin Respir Crit Care Med， 2014， 35（2）： 255-264.
9	FRANK M B， ITOH K， FUJISAKU A， et al. The mapping of the human 52-kD Ro/SSA autoantigen gene to human chromosome 11， and its polymorphisms［J］. Am J Hum Genet， 1993， 52（1）： 183-191.
10	GHILLANI P， ANDRÉC.， TOLY C， et al. Clinical significance of anti-Ro52 （TRIM21） antibodies non-associated with anti-SSA 60 kDa antibodies： Results of a multicentric study［J］. Autoimmunity Reviews， 2011， 10（9）：509-513.
11	FERREIRA J P， ALMEIDA I， MARINHO A， et al. Anti-ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma［J］. ISRN Rheumatol， 2012， 2012： 415272.
12	MARIE I， HATRON P Y， DOMINIQUE S， et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody［J］. Semin Arthritis Rheum， 2012， 41（6）： 890-899.
13	GUNNARSSON R， EL-HAGE F， AALØKKEN T M， et al. Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease［J］. Rheumatology （Oxford）， 2016， 55（1）： 103-108.
14	HUDSON M， POPE J， MAHLER M， et al. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis［J］. Arthritis Res Ther， 2012， 14（2）： R50.
15	WODKOWSKI M， HUDSON M， PROUDMAN S， et al. Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects： evidence of an association with interstitial lung disease and worse survival［J］. Clin Exp Rheumatol，2015，33（4 ）： S131-S135.
16	ITO I， NAGAI S， KITAICHI M， et al. Pulmonary manifestations of primary Sjogren’s syndrome： a clinical， radiologic， and pathologic study［J］. Am J Respir Crit Care Med， 2005， 171（6）： 632-638.
17	高辉，何菁，张学武，等. 原发性干燥综合征肺脏受累及其危险因素分析［J］. 中华风湿病学杂志， 2015， 19（5）： 306-312.
18	LIN W， XIN Z F， ZHANG J L， et al. Interstitial lung disease in Primary Sjögren’s syndrome［J］. BMC Pulm Med， 2022， 22（1）： 73.
19	GUO T， LONG Y M， SHEN Q X， et al. Clinical profiles of SS-ILD compared with SS-NILD in a Chinese population： a retrospective analysis of 735 patients［J］. Ann Med， 2021， 53（1）： 1340-1348.
20	徐杰，周贤梅，何海浪. 原发性干燥综合征合并间质性肺疾病临床分析［J］. 临床肺科杂志， 2016， 21（12）： 2209-2212.
21	QIN B D， WANG J Q， YANG Z X， et al. Epidemiology of primary Sjögren’s syndrome： a systematic review and meta-analysis［J］. Ann Rheum Dis， 2015， 74（11）： 1983-1989.
22	张頔. 原发性干燥综合征合并肺部受累临床分析［D］. 沈阳：中国医科大学， 2019.
23	WANG Y， HOU Z， QIU M， et al. Risk factors for primary Sjögren syndrome-associated interstitial lung disease［J］. J Thorac Dis， 2018， 10（4）： 2108-2117.
24	KAKUGAWA T， SAKAMOTO N， ISHIMOTO H， et al. Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjögren’s syndrome［J］. Respir Med， 2018， 137： 95-102.
25	GAO H， ZHANG X W， HE J， et al. Prevalence， risk factors， and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren syndrome patients：a case-control study［J］.Medicine，2018，97（24）： e11003.
26	HE C M， CHEN Z L， LIU S Y， et al. Prevalence and risk factors of interstitial lung disease in patients with primary Sjögren’s syndrome： a systematic review and meta-analysis［J］. Int J Rheum Dis， 2020， 23（8）： 1009-1018.
27	WENG L， CHEN Y， LIANG T，et al.Biomarkers of interstitial lung disease associated with primary Sjögren’s syndrome［J］.Eur J Med Res，2022，27（1）：199.

Group	n	Course of disease(month)	Age(year)	Femal [n(η/%)]	Hypertension [n(η/%)]	Diabetes [n(η/%)]	Smoking [n(η/%)]	Drinking alcohol [n(η/%)]
pSS complicated with ILD	21	24(4.5,36.0)	56(52.50,6.00)	21(100.0)	5(23.8)	1(4.8)	1(4.8)	1(4.8)
pSS complicated without ILD	155	24(5.0,60.0)	47(38.00,58.00)	149(96.1)	22(14.2)	1(0.6)	6(3.9)	1(0.6)
z/χ²		－0.813	－3.023	1.000	0.328	0.324	<0.01	0.329
P		0.416	<0.01	0.460	0.199	0.569	1.000	0.566

Group	n	HB [ρ_B/（g·L^－1)]	WBC (×10⁹ L^－1)		PLT (×10⁹ L^－1)		ESR （mm·h^－1）		CRP [ρ_B/(mg·L^－1)]		RF [λ_B/(IU·mL^－1)]
pSS complicated with ILD	21	115（106.5，128.0）	4.83（3.41，6.13）		211.62±87.32		112.0（69，127）		3.30（3.02，17.18）		12.6（11.0，44.7）
pSS complicated without ILD	155	117（108.0，128.0）	4.20（3.23，5.67）		190.94±88.34		36.5（19，57）		3.14（2.05，3.85）		13.1（11.0，63.1）
z/t		－0.032	－0.833		1.008		－5.610		－1.755		－0.612
P		0.975	0.405		0.315		0.001		0.079		0.541
Group	n	IgM[ρ_B/（g·L^－1)]		IgA[ρ_B/（g·L^－1)]		IgG[ρ_B/（g·L^－1)]		C3[ρ_B/（mg·L^－1)]		C4[ρ_B/（mg·L^－1)]
pSS complicated with ILD	21	1.41（0.90，2.08）		2.73（0.98，3.87）		19.60（13.65，24.25）		0.98（0.80，1.27）		0.20（0.15，0.27）
pSS complicated without ILD	155	1.21（0.88，1.74）		3.28（2.48，4.50）		19.10（15.20，24.20）		1.00（0.83，1.17）		0.19（0.14，0.25）
z/t		－1.146		－1.394		1.008		－0.256		－0.539
P		0.252		0.163		0.953		0.789		0.590

Group	n	Grain type antinuclear antibody(+)	Cytoplasmic granules type antinuclear antibody(+)	Homogeneous type antinuclear antibody(+)	Anti-SSA antibody(+)	Anti-SSB antibody(+)	Anti-Ro52 antibody(+)
pSS complicated with ILD	21	11（52.4）	11（52.4）	2（9.5）	21（100.0）	11（52.4）	14（66.7）
pSS complicated without ILD	155	115（74.2）	21（13.5）	32（20.6）	138（89.0）	78（50.3）	53（34.2）
z		0.073	16.230	0.841	1.148	0.031	8.272
P		0.787	<0.01	0.359	0.119	0.859	<0.01

Risk factor	Univariate analysis		Multivariate analysis
Risk factor	OR(95%CI)	P	OR(95%CI)	P
Age	1.058(1.016－1.102)	0.006	1.044(0.914－0.987)	0.132
ESR	1.054(1.034－1.074)	<0.01	1.046(1.026－1.066)	0.001
Cytoplasmic granules type antinuclear antibody(+)	7.019(2.655－18.555)	<0.01	4.476(1.560－18.916)	0.031
Anti-Ro52 antibody(+)	3.849(1.465－10.114)	0.006	2.792(0.772－10.102)	0.118

[1]	Xue DONG,Jinfeng ZANG,Caifeng XU,Hebing LIU,Zhaohua CHENG. Construction and validation of risk prediction model of enteral nutrition feeding intolerance of patients with severe acute pancreatitis [J]. Journal of Jilin University(Medicine Edition), 2023, 49(6): 1586-1592.
[2]	Peng QI,Xianying MENG,Meihua PIAO,Qiang ZHANG. Network Meta-analysis on risk factors of recurrence of papillary thyroid microcarcinoma [J]. Journal of Jilin University(Medicine Edition), 2023, 49(6): 1504-1512.
[3]	Tong SHEN,Yang WANG,Wei JIN,Zhihui LIN,Li YAN. Risk factors analysis and risk model construction of cognitive frailty in elderly patients with chronic diseases [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1304-1309.
[4]	Mingfei JU,Chao LIU,Zhigang MA,Juan ZHAO,Tu WANG,Zhihao WANG. Predictive value of residual cholesterol in occurrence of patients with acute coronary syndrome [J]. Journal of Jilin University(Medicine Edition), 2023, 49(3): 765-769.
[5]	Lianyuan WANG,Yi YANG,Huiwen CONG,Haohua WANG,Qihan BAO,Chengsheng LI,Liwen ZHOU,Zichen DING,Yanli LI,Fuyan SHI,Suzhen WANG. Bayesian quantile regression joint model analysis on risk factors of Alzheimer’s disease in people with different MMSE scores [J]. Journal of Jilin University(Medicine Edition), 2023, 49(2): 395-401.
[6]	Yidan QIN,Jia LI,Xiaochen PEI,Li LIU,Qinghui ZHANG,Jiajun CHEN. Central nervous system lymphoma complicated with Sjogren’s syndrome: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2023, 49(1): 209-214.
[7]	Shenghai TAN,Yi YUAN,Yandong ZHANG,Sanwei GU,Zhenyu JIANG. Coexistence of anti-Jo-1 and anti-SRP antibodies in dermatomyositis complicated with Sjogren’s syndrome: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2022, 48(4): 1028-1034.
[8]	Shan GAO,Yutong WANG,Minqiu LU,Lei SHI,Bin CHU,Yuehua DING,Mengzhen WANG,Li BAO. Analysis on causes for early death and its risk factors of patients with multiple myeloma in era of novel drugs [J]. Journal of Jilin University(Medicine Edition), 2022, 48(3): 783-789.
[9]	SU Kaisheng, ZHAO Ling, FENG Xiunan, JIANG Zhenyu. Antisynthetase syndrome with positive anti-Ro52 antibody: A report of 2 cases and literature review [J]. Journal of Jilin University(Medicine Edition), 2019, 45(04): 935-939.
[10]	ZHANG Haolong, YU Zhentao, GAO Zihan, WU Yuanyu, FANG Xuedong. Related risk factors and clinical treatment of patients with PGS after gastric cancer operation [J]. Journal of Jilin University(Medicine Edition), 2019, 45(03): 673-677.
[11]	PENG Yinyin, CHEN Liping, LIU Lin, CHEN Jianbin, CHEN Yajuan, HAN Xiaoli, XIAO Qing. Rituximab-induced interstitial lung disease:A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(06): 1260-1264.
[12]	JIANG Rui, LIU Fang, PAN Yueji, LU Boyang, HOU Lulu, WANG Chunmei, JIA Hui, SHI Xiaoru. Screening and analysis of dry eye in eye discomfort patients in Jilin Province [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 832-838.
[13]	ZHOU Hong, LIU Jincai, LUO Guanghua, XIE Peihan, YANG Juan, DONG Yulan, QING Weipeng, ZHANG Jingjing. Application of Coronary Artery Disease-Reporting and Data System in risk factor analysis of patients with coronary artery disease [J]. Journal of Jilin University Medicine Edition, 2017, 43(03): 617-622.
[14]	SI Henan, ZHONG Shuxia, ZHOU Junfeng, YAO Lei, LIU Yuanyuan, SONG Yang, LI Shanshan. Analysis on clinical characteristics and risk factors of 271 children with vitiligo [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 147-150.
[15]	GUO Li, ZHANG Xiaoxia, YU Meiling, ZHAO Ting, ZHANG Liqun. Preventive effect of hydroxyethyl starch solution on ovarian hyperstimulation syndrome [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1147-1150.

Analysis on clinical characteristics and risk factors of patients with Sjogren’s syndrome complicated with interstitial lung disease

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 27

Related Articles 15

Metrics

Comments

Recommended 2